Rentschler ups capacity again, with second 2,000L single-use bioreactor

By Dan Stanton

- Last updated on GMT

Image: Gc/o Rentschler
Image: Gc/o Rentschler

Related tags Stainless steel Biotechnology Steel

Biologics CMO Rentschler has increased its single-use capacity by 50%, just weeks after opening a stainless steel facility at its site in Germany.

Rentschler now house two 2,000L and two 1,000L bioreactors at its single-use facility in Laupheim, Germany, while a facility at the same site - which opened in September​ - offers drugmakers two 3,000 liter stainless steel bioreactor systems.

The contract manufacturing organisation (CMO) attributed the implementation of the new bioreactor to increased global demand for biologics manufacturing, and spokeswoman Marion Schrader said both big pharma and small biotech are looking for monoclonal antibody, antibody derived molecule, and biosimilar capacity.

Having both single-use and stainless steel capabilities allows the firm to capture more of this market, she told Biopharma-Reporter.

“The clients have different demands with regards to the scale of production, product characteristics, flexibility as well as technology,”​ she said. “Rentschler actively offers both single-use and stainless steel biomanufacturing to be flexible and to respond to clients’ needs.”

While drugmakers can opt for single-use equipment for small scale commercial manufacturing of, say, orphan drugs, the new twin stainless steel system which began operations in September, can offer larger volumes.

The two recent investments mirror a spate of expansions for the German CMO, and as such, Schrader told us the firm is looking to bolster its workforce.

“As we have made significant investments in new plant and facilities recently, the Rentschler workforce will continue to grow. Currently, Rentschler has a staff of 700 and we have an active on-going recruitment program.”

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us


View more